Please assess the completion status of the following clinical trial:

Trial Title: Knee Injection RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 18 who present with 1) symptomatic knee OA and radiographic evidence of joint space narrowing and 2) are interested in knee injections for pain relief.~Exclusion Criteria:~* Prior injections into the same knee within the past 6 months,~* Pregnant and/or lactating women,~* Inflammatory joint disease including rheumatoid or psoriatic arthritis,~* Concurrent use of anti-rheumatic drugs,~* Allergy or hypersensitivity to the study medications,~* Patients on an active pain management contract,~* Patients with insurance that requires pre-certification for any of the study drugs,~* Inability to make own decisions regarding the informed consent,~* Inability to read and/or understand English,~* Patients who are unable to return for follow-up or be reached by phone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketorolac (Type: EXPERIMENTAL): One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
- Corticosteroid (Type: ACTIVE_COMPARATOR): One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
- Hyaluronic Acid (Type: ACTIVE_COMPARATOR): One knee injection of Hylan G-F 20 (Synvisc-One)

Based on this trial design, predict the completion outcome and termination type (if applicable).